$VERU News

Oppenheimer Maintains Outperform on Veru, Lowers Price Target to $24

Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript

Transcript: Veru Q2 2026 Earnings Conference Call

Veru Q2 EPS $(0.12) Beats $(0.28) Estimate

Veru Files Prospectus For Offering $200M Mixed Shelf

Veru Enrolls First Patient In Phase 2b PLATEAU Clinical Trial Of Enobosarm, Oral SARM, To Preserve Muscle And Physical Function And To Augment Fat And Weight Loss When Combined With Wegovy

Veru Inc. (VERU) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Slideshow

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Veru Inc. Q1 2026 Earnings Call Summary

Veru Inc. (VERU) Q1 2026 Earnings Call Transcript

Veru (VERU) Q1 2026 Earnings Call Transcript

VERU INC (NASDAQ:VERU) Reports Narrower-Than-Expected Q1 Loss, Highlights Key Clinical Trial Timeline

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

Veru Q1 EPS $(0.26) Beats $(0.47) Estimate

A Look at Veru's Upcoming Earnings Report

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

VERU-111 Promotes An Anti-Tumor Response Through Restoration of Gut Microbial Homeostasis And Associated Metabolic Dysregulation

Canaccord Genuity Initiates Coverage On Veru with Buy Rating, Announces Price Target of $25

Veru Inc (VERU) Q4 2025 Earnings Call Highlights: Strategic Shifts and Financial Challenges